HCV Developing World Strategy


Bristol-Myers Squibb recognizes the significant public health challenge that hepatitis C virus (HCV) presents worldwide, including the substantial burden of the disease in the developing world. With more than 80% of the global HCV patient population living in low- and middle-income countries, there is great need for HCV treatment options in these countries. The significant challenges facing many of these countries are not homogeneous and beyond the reach of any one stakeholder to unilaterally address. A particular need continues to exist for governments, non-governmental organizations, civil society and industry to form coalitions to address the challenges.

 HCV Developing World Strategy

"We believe a coalition approach, which brings multiple stakeholders to the table to discuss the best path forward, is needed to enable broad access to HCV treatment over time. The challenge of HCV in the developing world cannot be address unilaterally by one stakeholder."

 

--Amadou Diarra, Head of Global Policy, Advocacy & Government Affairs


Bristol-Myers Squibb is continuing to strengthen our efforts to enable global access to DAKLINZA (daclatasvir). We have employed multiple approaches including tiered pricing in low- and middle-income countries, supplemented by a direct-import program in countries where we do not have plans to commercialize DAKLINZA. Our tiered pricing model for DAKLINZA takes into consideration several factors, including countries’ economic development and burden of disease, as well as the commitment of the government to holistically address hepatitis C, including treatment and care. The lowest pricing tier applies to all low-income and least developed countries.

Of significance, we have entered into the first-ever licensing agreement for a hepatitis C medicine with the Medicines Patent Pool (MPP), which provides a royalty-free license for daclatasvir (DAKLINZA) in a territory of 112 countries across the globe (see list below). Nearly two-thirds of all hepatitis C patients in low- and middle-income countries currently reside in the licensing territory, and in developing countries that are not included in this footprint, Bristol-Myers Squibb works with other stakeholders to enable access to DAKLINZA using other approaches. In 2016, DAKLINZA became the first-ever HCV medicine to gain WHO Pre-Qualification status.

Bristol-Myers Squibb has partnered with AmeriCares, the Clinton Health Access Initiative, Inc. (CHAI) and Duke University on a first-of-its-kind program in Africa and Southeast Asia aimed at curing HCV among patients co-infected with HCV and HIV. Bristol-Myers Squibb is donating free courses of DAKLINZA (daclatasvir) to treat 10,000 patients across Rwanda, Nigeria, Ethiopia, Myanmar, Vietnam, and Indonesia, where the initiative is being launched. The multi-year donation is designed to help the Clinton Health Access Initiative kick-start the program and provide a bridge to a sustainable access structure once licensed generic daclatasvir is available in these countries, and Clinton and its partners are able to work to address infrastructure challenges and other existing barriers to treatment.

Countries included in the licensing territory:

Afghanistan
Algeria
Angola
Azerbaijan
Bangladesh
Belize
Benin
Bhutan
Bolivia
Botswana
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo,
Democratic Republic
Congo, Republic
Cook Islands
Costa Rica
Cote d'Ivoire
Cuba
Djibouti
Dominica
Dominican Republic
Ecuador
El Salvador
Equatorial Guinea
Eritrea
Ethiopia
Fiji
Gabon
Gambia, The
Georgia
Ghana
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
India
Indonesia
Iraq
Jamaica
Kenya
Kiribati
Korea, Dem. Rep.
Laos
Lesotho
Liberia
Libya
Madagascar

Malawi
Maldives
Mali
Marshall Islands
Mauritania
Mauritius
Micronesia
Mongolia
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Nicaragua
Niger
Nigeria
Niue
Pacific Islands (Palau)
Pakistan
Panama
Papua New Guinea
Paraguay
Philippines
Rwanda
Samoa
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
Solomon Islands
Somalia
South Africa
South Sudan
Sri Lanka
Saint Lucia
Saint Vincent and the Grenadines
Sudan
Suriname
Swaziland
Syria
Timor-Leste
Togo
Tonga
Tunisia
Turkmenistan
Tuvalu
Uganda
United Republic of Tanzania
Uzbekistan
Vanuatu
Vietnam
West Bank
Yemen
Zambia
Zimbabwe